Nitroglycerin (Sublingual tablet): Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
GeraldChi (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
8,887 edits
No edit summary
GeraldChi (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
8,887 edits
No edit summary
Line 59: Line 59:
|offLabelAdultGuideSupport=
|offLabelAdultGuideSupport=


=====Condition1=====
=====Congestive Heart Failure, Myocardial Infarction with Complication=====


* Developed by:  
* Developed by: ACC/AHA


* Class of Recommendation:  
* Class of Recommendation: Class IIa


* Strength of Evidence:  
* Strength of Evidence: Category B


* Dosing Information
* Dosing Information


:* Dosage
:* Following acute myocardial infarction, early (less than 10 hours after onset) nitrate therapy resulted in limitations of infarct progression and arrhythmias and lowered the incidences of new congestive heart failure and early death.
:* Conversion to oral nitrates (isosorbide is best studied) or alternative routes of nitroglycerin administration should generally be accomplished within 24 to 48 hours.<ref>{{Cite journal | doi = 10.1016/j.jacc.2012.11.019 | issn = 1558-3597 | volume = 61 | issue = 4 | pages = –78-140 | last = American College of Emergency Physicians | coauthors = Society for Cardiovascular Angiography and Interventions, Patrick T. O'Gara, Frederick G. Kushner, Deborah D. Ascheim, Donald E. Casey, Mina K. Chung, James A. de Lemos, Steven M. Ettinger, James C. Fang, Francis M. Fesmire, Barry A. Franklin, Christopher B. Granger, Harlan M. Krumholz, Jane A. Linderbaum, David A. Morrow, L. Kristin Newby, Joseph P. Ornato, Narith Ou, Martha J. Radford, Jacqueline E. Tamis-Holland, Carl L. Tommaso, Cynthia M. Tracy, Y. Joseph Woo, David X. Zhao, Jeffrey L. Anderson, Alice K. Jacobs, Jonathan L. Halperin, Nancy M. Albert, Ralph G. Brindis, Mark A. Creager, David DeMets, Robert A. Guyton, Judith S. Hochman, Richard J. Kovacs, Frederick G. Kushner, E. Magnus Ohman, William G. Stevenson, Clyde W. Yancy | title = 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | journal = Journal of the American College of Cardiology | date = 2013-01-29 | pmid = 23256914 }}</ref><ref>{{Cite journal | issn = 0002-9149 | volume = 70 | issue = 8 | pages = 82–87B | last = Jugdutt | first = B. I. | title = Role of nitrates after acute myocardial infarction | journal = The American Journal of Cardiology | date = 1992-09-24 | pmid = 1529930 }}</ref><ref>{{Cite journal | issn = 0008-6312 | volume = 79 Suppl 2 | pages = 5–13 | last = Schneider | first = W. | coauthors = W. D. Bussmann, A. Hartmann, M. Kaltenbach | title = Nitrate therapy in heart failure | journal = Cardiology | date = 1991 | pmid = 1760830 }}</ref><ref>{{Cite journal | issn = 0009-7322 | volume = 78 | issue = 4 | pages = 906–919 | last = Jugdutt | first = B. I. | coauthors = J. W. Warnica | title = Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location | journal = Circulation | date = 1988-10 | pmid = 3139326 }}</ref>
:* In the immediate treatment of severe left ventricular failure following acute myocardial infarction, nitroglycerin combined with dobutamine lowered abnormally elevated left ventricular filling pressure and augmented left ventricular pump function resulting in optimal hemodynamics more beneficially than either therapy alone.<ref>{{Cite journal | issn = 0002-8703 | volume = 106 | issue = 1 Pt 1 | pages = 35–40 | last = Awan | first = N. A. | coauthors = M. K. Evenson, K. E. Needham, J. M. Beattie, D. T. Mason | title = Effect of combined nitroglycerin and dobutamine infusion in left ventricular dysfunction | journal = American Heart Journal | date = 1983-07 | pmid = 6408917 }}</ref><ref>{{Cite journal | issn = 0009-7322 | volume = 68 | issue = 4 | pages = 813–820 | last = Loeb | first = H. S. | coauthors = J. P. Ostrenga, W. Gaul, J. Witt, G. Freeman, P. Scanlon, R. M. Gunnar | title = Beneficial effects of dopamine combined with intravenous nitroglycerin on hemodynamics in patients with severe left ventricular failure | journal = Circulation | date = 1983-10 | pmid = 6413087 }}</ref>


=====Condition2=====
=====Condition2=====
Line 79: Line 81:
|offLabelAdultNoGuideSupport=
|offLabelAdultNoGuideSupport=


=====Condition1=====
=====Congestive Heart Failure, Myocardial Infarction with Complication=====


* Dosing Information
* Dosing Information


:* Dosage
 
xx


=====Condition2=====
=====Condition2=====

Revision as of 22:01, 20 July 2014

Nitroglycerin (Sublingual tablet)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Nitroglycerin (Sublingual tablet) is a anti-anginal vasodilator that is FDA approved for the {{{indicationType}}} of angina pectoris due to coronary artery disease. Common adverse reactions include hypotension, flushing, dizziness, headache, and lightheadedness.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Acute Relief of Angina Pectoris
  • Dosing Information
  • One tablet should be dissolved under the tongue or in the buccal pouch at the first sign of an acute anginal attack.
  • The dose may be repeated approximately every 5 minutes until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, prompt medical attention is recommended. NITROSTAT may be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.
  • During administration the patient should rest, preferably in the sitting position.
  • No dosage adjustment is required in patients with renal failure.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Congestive Heart Failure, Myocardial Infarction with Complication
  • Developed by: ACC/AHA
  • Class of Recommendation: Class IIa
  • Strength of Evidence: Category B
  • Dosing Information
  • Following acute myocardial infarction, early (less than 10 hours after onset) nitrate therapy resulted in limitations of infarct progression and arrhythmias and lowered the incidences of new congestive heart failure and early death.
  • Conversion to oral nitrates (isosorbide is best studied) or alternative routes of nitroglycerin administration should generally be accomplished within 24 to 48 hours.[1][2][3][4]
  • In the immediate treatment of severe left ventricular failure following acute myocardial infarction, nitroglycerin combined with dobutamine lowered abnormally elevated left ventricular filling pressure and augmented left ventricular pump function resulting in optimal hemodynamics more beneficially than either therapy alone.[5][6]
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Nitroglycerin (Sublingual tablet) in adult patients.

Non–Guideline-Supported Use

Congestive Heart Failure, Myocardial Infarction with Complication
  • Dosing Information


xx

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Nitroglycerin (Sublingual tablet) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Nitroglycerin (Sublingual tablet) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Nitroglycerin (Sublingual tablet) in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Nitroglycerin (Sublingual tablet) in pediatric patients.

Contraindications

  • Condition1

Warnings

  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Nitroglycerin (Sublingual tablet) in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Nitroglycerin (Sublingual tablet) in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Nitroglycerin (Sublingual tablet) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Nitroglycerin (Sublingual tablet) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Nitroglycerin (Sublingual tablet) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Nitroglycerin (Sublingual tablet) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Nitroglycerin (Sublingual tablet) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Nitroglycerin (Sublingual tablet) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Nitroglycerin (Sublingual tablet) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Nitroglycerin (Sublingual tablet) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Nitroglycerin (Sublingual tablet) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Nitroglycerin (Sublingual tablet) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Nitroglycerin (Sublingual tablet) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Nitroglycerin (Sublingual tablet) in the drug label.

Condition1
  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Nitroglycerin (Sublingual tablet) in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Nitroglycerin (Sublingual tablet) in the drug label.

Pharmacology

There is limited information regarding Nitroglycerin (Sublingual tablet) Pharmacology in the drug label.

Mechanism of Action

Structure

File:Nitroglycerin (Sublingual tablet)01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Nitroglycerin (Sublingual tablet) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Nitroglycerin (Sublingual tablet) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Nitroglycerin (Sublingual tablet) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Nitroglycerin (Sublingual tablet) in the drug label.

Condition1
  • Description

How Supplied

Storage

There is limited information regarding Nitroglycerin (Sublingual tablet) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Nitroglycerin (Sublingual tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Nitroglycerin (Sublingual tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Nitroglycerin (Sublingual tablet) in the drug label.

Precautions with Alcohol

  • Alcohol-Nitroglycerin (Sublingual tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • Minitran®
  • Nitro-Bid®
  • Nitro-Dur®
  • Nitrolingual®
  • Nitrostat®
  • Nitrotab®
  • Nitrek®
  • NitroMist®
  • Nitrostat®[7]

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ American College of Emergency Physicians (2013-01-29). "2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Journal of the American College of Cardiology. 61 (4): –78-140. doi:10.1016/j.jacc.2012.11.019. ISSN 1558-3597. PMID 23256914. Unknown parameter |coauthors= ignored (help)
  2. ↑ Jugdutt, B. I. (1992-09-24). "Role of nitrates after acute myocardial infarction". The American Journal of Cardiology. 70 (8): 82–87B. ISSN 0002-9149. PMID 1529930.
  3. ↑ Schneider, W. (1991). "Nitrate therapy in heart failure". Cardiology. 79 Suppl 2: 5–13. ISSN 0008-6312. PMID 1760830. Unknown parameter |coauthors= ignored (help)
  4. ↑ Jugdutt, B. I. (1988-10). "Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location". Circulation. 78 (4): 906–919. ISSN 0009-7322. PMID 3139326. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)
  5. ↑ Awan, N. A. (1983-07). "Effect of combined nitroglycerin and dobutamine infusion in left ventricular dysfunction". American Heart Journal. 106 (1 Pt 1): 35–40. ISSN 0002-8703. PMID 6408917. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)
  6. ↑ Loeb, H. S. (1983-10). "Beneficial effects of dopamine combined with intravenous nitroglycerin on hemodynamics in patients with severe left ventricular failure". Circulation. 68 (4): 813–820. ISSN 0009-7322. PMID 6413087. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)
  7. ↑ "NITROSTAT (nitroglycerin) tablet".
  8. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Nitroglycerin (Sublingual tablet)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Nitroglycerin (Sublingual tablet)
 |Label Name=Nitroglycerin (Sublingual tablet)04.png

}}


{{#subobject: 

 |Label Page=Nitroglycerin (Sublingual tablet)
 |Label Name=Nitroglycerin (Sublingual tablet)05.png

}}


{{#subobject: 

 |Label Page=Nitroglycerin (Sublingual tablet)
 |Label Name=Nitroglycerin (Sublingual tablet)06.png

}}


{{#subobject: 

 |Label Page=Nitroglycerin (Sublingual tablet)
 |Label Name=Nitroglycerin (Sublingual tablet)07.png

}}


{{#subobject: 

 |Label Page=Nitroglycerin (Sublingual tablet)
 |Label Name=Nitroglycerin (Sublingual tablet)08.png

}}


{{#subobject: 

 |Label Page=Nitroglycerin (Sublingual tablet)
 |Label Name=Nitroglycerin (Sublingual tablet)09.png

}}


{{#subobject: 

 |Label Page=Nitroglycerin (Sublingual tablet)
 |Label Name=Nitroglycerin (Sublingual tablet)10.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Nitroglycerin_(Sublingual_tablet)&oldid=996100"